NCT02206152View on ClinicalTrials.gov

A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Type 1 DiabetesHypoglycemia Unawareness
Interventions
DRUG

N-acetyl cysteine

N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp

DRUG

Placebo

Trial Locations (1)

55455

University of Minnesota Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02206152 - A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter